vTv Therapeutics (NASDAQ:VTVT) Stock Crosses Above Fifty Day Moving Average – Here’s Why

vTv Therapeutics Inc. (NASDAQ:VTVT) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $19.30 and traded as high as $19.45. vTv Therapeutics shares last traded at $17.76, with a volume of 4,707 shares trading hands.

Wall Street Analysts Forecast Growth

VTVT has been the topic of several recent analyst reports. Wall Street Zen initiated coverage on vTv Therapeutics in a report on Wednesday, April 16th. They issued a “sell” rating on the stock. HC Wainwright began coverage on vTv Therapeutics in a research note on Wednesday, April 9th. They issued a “buy” rating and a $36.00 target price on the stock.

vTv Therapeutics Trading Down 8.7%

The company has a market capitalization of $56.65 million, a PE ratio of -3.92 and a beta of 0.77. The firm’s 50-day simple moving average is $19.30 and its 200-day simple moving average is $17.11.

vTv Therapeutics (NASDAQ:VTVT) last announced its quarterly earnings results on Thursday, May 15th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.04).

Institutional Investors Weigh In On vTv Therapeutics

Hedge funds have recently made changes to their positions in the company. Connective Capital Management LLC purchased a new position in shares of vTv Therapeutics during the first quarter valued at $162,000. Geode Capital Management LLC grew its holdings in vTv Therapeutics by 12.9% during the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after acquiring an additional 1,327 shares in the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in vTv Therapeutics during the 4th quarter valued at about $25,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.